Erratum: Disruption of myc-max heterodimerization with improved cell-penetrating analogs of the small molecule 10074-G5 (Oncotarget (2013) 4 (936-947) DOI: 10.18632/oncotarget.1108);Disruption of Myc-Max heterodimerization with improved cell- penetrating analogs of the small molecule 10074-G5

Oncotarget

Volumn 4, Issue 6, 2013, Pages 936-947

  Wang, Huabo ^a   Chauhan, Jay ^b   Hu, Angela ^a   Pendleton, Kelsey ^a   Yap, Jeremy L ^b   Sabato, Philip E ^b   Jones, Jace W ^b   Perri, Mariarita ^c   Yu, Jianshi ^b   Cione, Erika ^c   Kane, Maureen A ^b,d   Fletcher, Steven ^b,d   Prochownik, Edward V ^a,e,f  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c UNIVERSITY OF CALABRIA   (Italy)

^d UNIVERSITY OF MARYLAND   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

10058 F4; 10074 G5; BRD4; Intrinsically disordered proteins; JQ 1

Indexed keywords

CARBOXYLIC ACID; ESTERASE; MAX PROTEIN; ONCOPROTEIN;

ARTICLE; CYTOPLASM; DIMERIZATION; ESTERIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR LIBRARY; ONCOGENE C MYC; PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BINDING SITES; HEK293 CELLS; HUMANS; MASS SPECTROMETRY; OXADIAZOLES; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-MYC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84880799558     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1108     Document Type: Erratum

References (47)

1. Arkin MR and Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov. 2004; 3(4):301-317.
2. Berg T. Small-molecule inhibitors of protein-protein interactions. Curr Opin Drug Discov Devel. 2008; 11(5):666-674.
3. Fletcher S and Hamilton AD. Targeting protein-protein interactions by rational design: mimicry of protein surfaces. J R Soc Interface. 2006; 3(7):215-233.
4. Wells JA and McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007; 450(7172):1001-1009.
5. Yap JL, Chauhan J, Jung K-Y, Chen L, Prochownik EV and Fletcher S. Small-molecule inhibitors of dimeric transcription factors: Antagonism of protein-protein and protein-DNA interactions. MedChemComm. 2012; 3(5):541-551.
6. Prochownik EV and Vogt PK. Therapeutic Targeting of Myc. Genes Cancer. 2010; 1(6):650-659.
7. Berg T. Small-molecule modulators of c-Myc/Max and Max/Max interactions. Curr Top Microbiol Immunol. 2011; 348:139-149.
8. Dudkina AS and Lindsley CW. Small molecule protein protein inhibitors for the p53-MDM2 interaction. Curr Top Med Chem. 2007; 7(10):952-960.
9. Patel S and Player MR. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin Investig Drugs. 2008; 17(12):1865-1882.
10. Yap JL, Cao X, Vanommeslaeghe K, Jung KY, Peddaboina C, Wilder PT, Nan A, MacKerell AD, Jr., Smythe WR and Fletcher S. Relaxation of the rigid backbone of an oligoamide-foldamer-based alpha-helix mimetic: identification of potent Bcl-xL inhibitors. Org Biomol Chem. 2012; 10(15):2928-2933.
11. Richardson A and Kaye SB. Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy. Curr Mol Pharmacol. 2008; 1(3):244-254.
12. Nesbit CE, Tersak JM and Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999; 18(19):3004-3016.
13. Chen Y and Olopade OI. MYC in breast tumor progression. Expert Rev Anticancer Ther. 2008; 8(10):1689-1698.
14. Meyer N and Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8(12):976-990.
15. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S and Evan GI. Modelling Myc inhibition as a cancer therapy. Nature. 2008; 455(7213):679-683.
16. Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV, Prochownik EV and Nikiforov MA. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene. 2008; 27(13):1905-1915.
17. Felsher DW. MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer. 2010; 1(6):597-604.
18. Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI and Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011; 25(9):907-916.
19. Soucek L, Whitfield JR, Sodir NM, Masso-Valles D, Serrano E, Karnezis AN, Swigart LB and Evan GI. Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. Genes Dev. 2013; 27(5):504-513.
20. Berg T, Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, Goldberg J, Boger DL and Vogt PK. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A. 2002; 99(6):3830-3835.
21. Yin X, Giap C, Lazo JS and Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene. 2003; 22(40):6151-6159.
22. Kiessling A, Sperl B, Hollis A, Eick D and Berg T. Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol. 2006; 13(7):745- 751.
23. Wang H, Hammoudeh DI, Follis AV, Reese BE, Lazo JS, Metallo SJ and Prochownik EV. Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther. 2007; 6(9):2399-2408.
24. Lu X, Vogt PK, Boger DL and Lunec J. Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncol Rep. 2008; 19(3):825-830.
25. Mustata G, Follis AV, Hammoudeh DI, Metallo SJ, Wang H, Prochownik EV, Lazo JS and Bahar I. Discovery of novel Myc-Max heterodimer disruptors with a threedimensional pharmacophore model. J Med Chem. 2009; 52(5):1247-1250.
26. Shi J, Stover JS, Whitby LR, Vogt PK and Boger DL. Small molecule inhibitors of Myc/Max dimerization and Mycinduced cell transformation. Bioorg Med Chem Lett. 2009; 19(21):6038-6041.
27. Jeong KC, Ahn KO and Yang CH. Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest. Mol Biosyst. 2010; 6(8):1503-1509.
28. Yap JL, Wang H, Hu A, Chauhan J, Jung KY, Gharavi RB, Prochownik EV and Fletcher S. Pharmacophore identification of c-Myc inhibitor 10074-G5. Bioorg Med Chem Lett. 2012; 23(1):370-374.
29. Dunker AK, Silman I, Uversky VN and Sussman JL. Function and structure of inherently disordered proteins. Curr Opin Struct Biol. 2008; 18(6):756-764.
30. Metallo SJ. Intrinsically disordered proteins are potential drug targets. Curr Opin Chem Biol. 2010; 14(4):481-488.
31. Uversky VN. Multitude of binding modes attainable by intrinsically disordered proteins: a portrait gallery of disorder-based complexes. Chem Soc Rev. 2010; 40(3):1623-1634.
32. Fieber W, Schneider ML, Matt T, Krautler B, Konrat R and Bister K. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc. J Mol Biol. 2001; 307(5):1395- 1410.
33. Follis AV, Hammoudeh DI, Wang H, Prochownik EV and Metallo SJ. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol. 2008; 15(11):1149-1155.
34. Hammoudeh DI, Follis AV, Prochownik EV and Metallo SJ. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc. 2009; 131(21):7390-7401.
35. Harvey SR, Porrini M, Stachl C, MacMillan D, Zinzalla G and Barran PE. Small-molecule inhibition of c-MYC:MAX leucine zipper formation is revealed by ion mobility mass spectrometry. J Am Chem Soc. 2012; 134(47):19384- 19392.
36. Guo J, Parise RA, Joseph E, Egorin MJ, Lazo JS, Prochownik EV and Eiseman JL. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4- ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol. 2009; 63(4):615-625.
37. Clausen DM, Guo J, Parise RA, Beumer JH, Egorin MJ, Lazo JS, Prochownik EV and Eiseman JL. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther. 2010; 335(3):715-727.
38. Follis AV, Hammoudeh DI, Daab AT and Metallo SJ. Small-molecule perturbation of competing interactions between c-Myc and Max. Bioorg Med Chem Lett. 2009; 19(3):807-810.
39. Wang B, Siahaan T and Soltero R. (2005). Drug delivery: principles and applications. (Hoboken, N.J.: Wiley- Interscience).
40. White A. Effect of pH on fluorescence of tryosine, tryptophan and related compounds. Biochem J. 1959; 71(2):217-210.
41. Tomasic T and Masic LP. Rhodanine as a privileged scaffold in drug discovery. Curr Med Chem. 2009; 16(13):1596-1629.
42. Tomasic T and Masic LP. Rhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation. Expert Opinion on Drug Discovery. 2012; 7(7):549-560.
43. Blackwood EM and Eisenman RN. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science. 1991; 251(4998):1211-1217.
44. Zhang H, Fan S and Prochownik EV. Distinct roles for MAX protein isoforms in proliferation and apoptosis. J Biol Chem. 1997; 272(28):17416-17424.
45. Prochownik EV and VanAntwerp ME. Differential patterns of DNA binding by myc and max proteins. Proc Natl Acad Sci U S A. 1993; 90(3):960-964.
46. Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN and Weintraub H. Sequence-specific DNA binding by the c-Myc protein. Science. 1990; 250(4984):1149-1151.
47. Rothermund K, Rogulski K, Fernandes E, Whiting A, Sedivy J, Pu L and Prochownik EV. C-Myc-independent restoration of multiple phenotypes by two C-Myc target genes with overlapping functions. Cancer Res. 2005; 65(6):2097-2107